000293941 001__ 293941
000293941 005__ 20241013013209.0
000293941 0247_ $$2doi$$a10.2147/CLEP.S467874
000293941 0247_ $$2pmid$$apmid:39371051
000293941 0247_ $$2pmc$$apmc:PMC11456301
000293941 0247_ $$2altmetric$$aaltmetric:169103851
000293941 037__ $$aDKFZ-2024-02008
000293941 041__ $$aEnglish
000293941 082__ $$a610
000293941 1001_ $$aZitricky, Frantisek$$b0
000293941 245__ $$aSurvival in Thyroid Cancer in Sweden From 1999 To 2018.
000293941 260__ $$aAlbany, Auckland$$bDove Medical Press$$c2024
000293941 3367_ $$2DRIVER$$aarticle
000293941 3367_ $$2DataCite$$aOutput Types/Journal article
000293941 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1728310759_26555
000293941 3367_ $$2BibTeX$$aARTICLE
000293941 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000293941 3367_ $$00$$2EndNote$$aJournal Article
000293941 500__ $$a#LA:Z999#
000293941 520__ $$aThyroid cancer (TC) is diagnosed in several histological types which differ in their clinical characteristics and survival. We aim to describe how they influence TC survival in Sweden.Cancer data were obtained from the Swedish cancer registry between years 1999 and 2018, and these were used to analyze relative survival.Relative survival for all TC improved when analyzed in 10-year periods, and female survival improved more than male survival. Female survival advantage appeared to be present also for specific histological types, although case numbers were low for rare types. Female 5-year relative survival for TC was 100% for follicular, 95.1% for oncocytic, 93.4% for papillary, 89.7% for medullary, and 6.1% for anaplastic cancer. Among the clinical TNM classes, only T4 and M1 stages were associated with decreased survival compared to T1-3 and M0. Anaplastic cancer presented most often at high T and M1 stages, in contrast to other TC. Curiously, the diagnostic age for anaplastic M1 patients was lower than that for M0 patients. Both anaplastic and medullary cancers did not show age-dependent increases in the probability of metastases, in contrast to the main histological types. This could indicate the presence of several types of anaplastic and medullary cancers.The poor survival for anaplastic TC is an extreme contrast to the excellent survival of differentiated TC. As less than 20% of anaplastic cancer patients survived one year, urgent diagnosis and initiation of treatment are important. Facilitated treatment pathways have been instituted in Denmark resulting in improved survival. Anaplastic cancer should be a target of a major research focus.
000293941 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000293941 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000293941 650_7 $$2Other$$aanaplastic cancer
000293941 650_7 $$2Other$$ametastasis
000293941 650_7 $$2Other$$aprognosis
000293941 650_7 $$2Other$$arelative survival
000293941 650_7 $$2Other$$atrends
000293941 7001_ $$aKoskinen, Anni$$b1
000293941 7001_ $$aSundquist, Kristina$$b2
000293941 7001_ $$00000-0001-7228-5015$$aSundquist, Jan$$b3
000293941 7001_ $$aLiska, Vaclav$$b4
000293941 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b5$$udkfz
000293941 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b6
000293941 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b7$$eLast author$$udkfz
000293941 773__ $$0PERI:(DE-600)2494772-6$$a10.2147/CLEP.S467874$$gVol. 16, p. 659 - 671$$p659 - 671$$tClinical epidemiology$$v16$$x1179-1349$$y2024
000293941 909CO $$ooai:inrepo02.dkfz.de:293941$$pVDB
000293941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000293941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000293941 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000293941 9141_ $$y2024
000293941 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN EPIDEMIOL : 2022$$d2023-08-22
000293941 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-22
000293941 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-22
000293941 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-22
000293941 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-10-14T20:47:13Z
000293941 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-10-14T20:47:13Z
000293941 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-10-14T20:47:13Z
000293941 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-22
000293941 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-22
000293941 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-22
000293941 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-22
000293941 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-22
000293941 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-22
000293941 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-22
000293941 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-22
000293941 9202_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x0
000293941 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000293941 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000293941 9201_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x2
000293941 980__ $$ajournal
000293941 980__ $$aVDB
000293941 980__ $$aI:(DE-He78)B062-20160331
000293941 980__ $$aI:(DE-He78)HD01-20160331
000293941 980__ $$aI:(DE-He78)Z999-20160331
000293941 980__ $$aUNRESTRICTED